The Revenue Lifecycle of a Drug
A drug’s commercial life follows a predictable arc. After FDA approval, revenue ramps slowly in the first 1–2 years as the sales force builds out, physicians gain familiarity, and payer coverage expands. It then enters a growth phase where revenue accelerates as market penetration increases. Peak sales typically occurs 5–8 years after launch. After that, revenue declines as patents expire and generics enter.
The entire lifecycle from launch to generic erosion is 12–15 years. Peak sales — the maximum annual revenue — is the single most important number in valuing a pre-revenue biotech company. Blockbuster status means $1 billion+ per year.
When analysts value a pre-revenue biotech, they’re estimating peak sales and discounting backward. A drug projected to reach $3B in peak sales makes the entire company worth dramatically more than one projected at $300M — even before a single prescription is written.
What Determines Peak Sales
Three factors determine a drug’s peak sales potential: patient population size, price per treatment, and expected market share.
Patient Population
A drug for metastatic melanoma (~100,000 U.S. patients annually) has a smaller addressable market than a drug for Type 2 diabetes (37 million Americans). But rare disease drugs can reach blockbuster status through ultra-high pricing — $300,000–$500,000 per patient per year.
Pricing
| Drug Type | Typical Price Range | Example |
|---|---|---|
| Small molecule pills | $1K–$5K/month | Oral oncology drugs |
| Biologics | $10K–$30K/month | Monoclonal antibodies |
| Gene therapies | $1M–$3M/patient | One-time curative treatments |
Market Share
First-in-class drugs with a novel mechanism of action capture 40–60% of the addressable market. Me-too drugs entering crowded therapeutic areas capture 10–15%. This is why "first-in-class" and "best-in-class" are the two phrases that get biotech investors most excited.
How This Affects Catalyst Trading
A PDUFA date for a drug with $5B peak sales potential is a bigger event than one with $500M — but a micro-cap biotech with the $500M drug might see a larger percentage move because it represents the company’s entire value. This is why catalyst scoring systems weight both commercial potential and market cap.
The relationship between peak sales and stock movement isn’t linear. What matters is the ratio of projected peak sales to current market capitalization. A $200M market cap company with a $2B peak sales drug has a 10:1 ratio — an approval can easily double or triple the stock. A $100B company with the same $2B drug? That’s a 2% revenue addition. The stock might move 5%.
The highest-volatility catalyst events combine large peak sales potential with small market capitalization. This is the “materiality” factor that drives Bio-Score™ calculations — a $2B drug inside a $200M company is a powder keg.
The Patent Cliff: When Revenue Dies
Every drug has an expiration date. When patents expire, revenue drops 80–90% within two years as generic competitors flood the market at a fraction of the branded price. This isn’t gradual — it’s a cliff.
Pfizer lost $10B in annual revenue when Lipitor went generic. AbbVie’s entire corporate strategy for a decade has been managing the Humira patent cliff. Upcoming patent expirations are predictable catalysts — already priced in somewhat, but the actual decline often exceeds expectations.
For traders, patent cliffs create a different kind of catalyst. The expiration date is known years in advance, but the speed of generic erosion and the success of replacement drugs are the unknowns. Companies that fail to replenish their pipeline before a patent cliff face existential risk.
Related Articles
BioCatalysts.AI tracks the catalysts that move biotech stocks.
Revenue potential is one input. See how Bio-Score™ combines it with event tier and urgency to rank every upcoming catalyst.
Open App →